Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICAM1 | P05362 | 8/20 | 0.35 |
| ▸ | SELE | P16581 | 8/20 | 0.35 |
| ▸ | VCAM1 | P19320 | 5/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | VEGFA | P15692 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19274478 | 0.88 | PDPK1 (0.42) | ICAM1SELEVCAM1NTRK1VEGFA | |
| SCHEMBL19259596 | 0.86 | PCSK9 (0.36) | LOXL2 | |
| SCHEMBL19259936 | 0.85 | LOXL2 (0.38) | NTRK1LOXL3LOXL2MEN1KMT2A | |
| SCHEMBL19259640 | 0.82 | LOXL2 (0.44) | LOXL3LOXL2VEGFAFLT1EGLN1 | |
| SCHEMBL19259800 | 0.81 | LOXL2 (0.44) | NTRK1LOXL3LOXL2VEGFAFLT1 | |
| SCHEMBL19259998 | 0.80 | MAPT (0.36) | NTRK1LOXL3LOXL2MEN1KMT2A | |
| SCHEMBL19259903 | 0.79 | LOXL2 (0.38) | NTRK1LOXL3LOXL2MEN1KMT2A | |
| SCHEMBL19259976 | 0.75 | ABL1 (0.40) | NTRK1LOXL3LOXL2EGLN1EGLN3 | |
| SCHEMBL19259871 | 0.75 | LOXL2 (0.52) | NTRK1LOXL3LOXL2 | |
| SCHEMBL19259784 | 0.75 | LOXL2 (0.42) | LOXL3LOXL2EGLN1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416956-B1 | METHYLAMINE DERIVATIVES AS LYSYL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2023-03-21 | — | — | US | disclosed |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-05-04 | — | — | US | disclosed |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-02-11 | — | — | US | disclosed |
| US-10807974-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-10-20 | — | — | US | disclosed |
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-05-23 | — | — | US | disclosed |
| EP-3416956-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | The Institute of Cancer Research : The Royal Cancer Hospital (GB) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017141049-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | ICAM1 4516/4885SELE 2528/4885VCAM1 3559/4885 |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | ICAM1 4516/4885SELE 2528/4885VCAM1 3559/4885 |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | ICAM1 4516/4885SELE 2528/4885VCAM1 3559/4885 |
| US-10807974-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | ICAM1 4516/4885SELE 2528/4885VCAM1 3559/4885 |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | ICAM1 4516/4885SELE 2528/4885VCAM1 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.